Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 22, 2017
What is the competitive landscape for SANOFI AVENTIS US, and when can generic versions of SANOFI AVENTIS US drugs launch?
SANOFI AVENTIS US has one hundred and thirty-six approved drugs.| Patents: | 56 |
| Tradenames: | 113 |
| Ingredients: | 93 |
| NDAs: | 136 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | BRICANYL | terbutaline sulfate | INJECTABLE;INJECTION | 017466-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Sanofi Aventis Us | APIDRA SOLOSTAR | insulin glulisine recombinant | INJECTABLE;SUBCUTANEOUS | 021629-003 | Feb 24, 2009 | RX | Yes | No | 6,221,633 | ► Subscribe | Y | Y | ► Subscribe | ||||||||||||||||
Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Sanofi Aventis Us | AZOLID | phenylbutazone | TABLET;ORAL | 087091-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Sanofi Aventis Us | CHILDREN'S ALLEGRA HIVES | fexofenadine hydrochloride | SUSPENSION;ORAL | 201373-002 | Jan 24, 2011 | OTC | Yes | Yes | 6,037,353*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | CHILDREN'S ALLEGRA HIVES | fexofenadine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021909-003 | Jan 24, 2011 | 7,138,524 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-006 | Jun 2, 2000 | 5,389,618 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-006 | Jun 2, 2000 | RE38743 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | TORNALATE | bitolterol mesylate | AEROSOL, METERED;INHALATION | 018770-001 | Dec 28, 1984 | 4,336,400 | ► Subscribe | ||||||||||||||||||||||
Sanofi Aventis Us | TAXOTERE | docetaxel | INJECTABLE;INJECTION | 020449-001 | May 14, 1996 | 5,698,582*PED | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
nicotine | Transdermal System | 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs | NICODERM CQ | 5/30/2014 |
dronedarone hydrochloride | Tablets | 400 mg | MULTAQ | 7/1/2013 |
oxaliplatin | Injection | 5 mg/mL, 40 mL vial | ELOXATIN | 3/23/2011 |
fexofenadine hydrochloride | Oral Suspension | 30 mg/5 mL | ALLEGRA | 1/25/2010 |
docetaxel | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | TAXOTERE | 6/30/2009 |
clopidogrel bisulfate | Tablets | 300 mg | PLAVIX | 3/4/2009 |
oxaliplatin | Injection | 200 mg/40 mL | ELOXATIN | 7/16/2007 |
oxaliplatin | Injection | 5 mg/mL, 10 mL and 20 mL vials | ELOXATIN | 2/9/2007 |
oxaliplatin | For Injection | 50 mg/vial and 100 mg/vial | ELOXATIN | 2/9/2007 |
enoxaparin sodium | Injection | 100 mg/mL, 3 mL vials | LOVENOX | 12/7/2006 |
irbesartan and hydrochlorothiazide | Tablets | 300 mg/25 mg | AVALIDE | 6/6/2006 |
zolpidem tartrate | Extended-release Tablets | 6.25 mg | AMBIEN CR | 2/24/2006 |
zolpidem tartrate | Extended-release Tablets | 12.5 mg | AMBIEN CR | 1/19/2006 |
irbesartan and hydrochlorothiazide | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | AVALIDE | 11/10/2004 |
irbesartan | Tablets | 75 mg, 150 mg and 300 mg | AVAPRO | 5/25/2004 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,122,206 | Aqueous-based pharmaceutical composition | ► Subscribe | |||||||||||||||||||||||||||
| 9,028,454 | Drive mechanisms suitable for use in drug delivery devices | ► Subscribe | |||||||||||||||||||||||||||
| 7,205,277 | Zinc-free and low-zinc insulin preparations having improved stability | ► Subscribe | |||||||||||||||||||||||||||
| 8,021,345 | Pen-type injector | ► Subscribe | |||||||||||||||||||||||||||
| 9,526,843 | Drive mechanisms suitable for use in drug delivery devices | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Israel | 127611 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1007030 | ► Subscribe | |||||||||||||||||||||||||||
| Austria | 397917 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 1114100 | ► Subscribe | |||||||||||||||||||||||||||
| Poland | 341659 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00597 | Netherlands | ► Subscribe | PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121 | ||||||||||||||||||||||||||
| 90035 | Sweden | ► Subscribe | PRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715 | ||||||||||||||||||||||||||
| 2107069/01 | Switzerland | ► Subscribe | PRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013 | ||||||||||||||||||||||||||
| 2015 00014 | Denmark | ► Subscribe | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 | ||||||||||||||||||||||||||
| 172 | Luxembourg | ► Subscribe | PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL) | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,076 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
